TransEnterix Doesn’t Have What It Takes to Be a Long-Term Investment
TransEnterix (NYSE:TRXC), which develops robots used in surgeries, has a chance to become a great company. Unfortunately, the medical-device maker’s relative weakness in the U.S., its tough competition and its low revenue prevent me from recommending TRXC stock at this time.
TransEnterix has developed a few revenue-generating niches that let it compete in the robotic-surgery market despite the presence of the much larger and more successful Intuitive Surgical (NASDAQ:ISRG).
TransEnterix has developed robots that specialize in facilitating laparoscopic surgeries and allow surgeons to sit while conducting procedures.
Further, TransEnterix’s Senhance robotic system uses smaller “articulating instruments” than Intuitive Surgical’s Da Vinci, allowing Senhance to be more precise, according to BOOX Research via Seeking Alpha. Senhance’s smaller size also makes it better suited to pediatric surgeries, TransEnterix claims.
What’s more, Senhance’s instruments are reusable while Da Vinci typically requires limited usage (10-15 procedures). According to the BOOX story, this makes Da Vinci’s instruments more expensive.
TRXC Stock and U.S. Operations
TransEnterix’s sales appear to be much stronger in Europe and Asia than in the U.S. There are a few indications of this phenomenon.
On the company’s third-quarter earnings call, CEO Anthony Fernando reported strong demand for Senhance particularly in Asia. TransEnterix, he said, should continue to see growth in the region. The company also is doing well in Europe, he said.
After reviewing the transcript of the call, I couldn’t find similar upbeat comments about the U.S.
Further, Fernando reported that, in Asia, the number of procedures carried out using TransEnterix’s system had jumped 37% year-over-year in Q3. Although procedure volume had tumbled about 28% YOY in Q3 in Europe, volumes had surged almost 200% versus Q2. When it came to U.S. procedures, his only note was that they were off 11% year-over-year.
Finally, Fernando noted that in Q3, TransEnterix had “initiated clinical programs at three new sites, two in Europe, and one in Japan.” Obviously, the company did not launch any clinical programs in the U.S. in Q3.
Tough Competition and Little Revenue
In addition to Intuitive Surgical, other companies that are much larger than TransEnterix appear to be entering the robotic surgery market.
On the earnings conference call, an analyst asked Fernando whether competitors like Medtronic (NYSE:MDT) posed a greater threat than before. Medtronic announced it has launched both robotic and digital surgery solutions.
Fernando responded that, although competition was heating up, the market was huge and untapped. It wasn’t a pressing concern for him, but maybe it should be.
Much bigger players like Medtronic and Intuitive Surgical could create major problems for TransEnterix, putting pressure on TRXC stock if they decide to provide robotic solutions for laparoscopies.
Finally, the company generated just $8.5 million of revenue in 2019 and $2.75 million of sales over the 12 months that ended in September.
The Bottom Line on TXRC Stock
With TransEnterix generating very little revenue, apparently not generating a large amount of interest in the U.S. and facing tough competitive threats, investors should avoid the stock for now. I would advise those who already own the shares to take some profits on it.
On the date of publication, Larry Ramer did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Larry Ramer has conducted research and written articles on U.S. stocks for 13 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been GE, solar stocks, and Snap. You can reach him on StockTwits at @larryramer.